Drawing for PASMAX

USPTO serial 86919081

PASMAX

Reviewed by CopyMark Law Group

Reg. 5067522Status 710
Filing date
Status date
Registration date
Oct 25, 2016
Examiner
HOLTZ, ALLISON
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with PASMAX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
001Active chemical ingredients and solvents for use in the manufacture of insecticides; Active chemical ingredients for use in the manufacture of anti-cancer drugs; Chemicals for use in biotechnological product development; Chemicals for use in biotechnological manufacturing processesSECTION 8 - CANCELLED—
005Chemical reagents for medical or veterinary purposes; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations, namely, antivirals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Cytostatics for pharmaceutical purposes; Drug delivery agents in the form of molecular solubility enhancer that facilitate the delivery of pharmaceutical preparations; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicineSECTION 8 - CANCELLED—
042Chemical laboratories; Chemical research; Drug discovery services; Pharmaceutical drug development services; Pharmaceutical research and development; Pharmaceutical research services; Conducting early evaluations in the field of new pharmaceuticals; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Development of pharmaceutical preparations and medicines; Development of pharmaceutical preparations and medicines; Laboratory research services relating to pharmaceuticals; Pharmaceutical drug development services; Research and development in the pharmaceutical and biotechnology fields; Research in the field of Antibody drug conjugatesSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 5, 2023C8..CANCELLED SEC. 8 (6-YR)—
Oct 25, 2021REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Oct 25, 2016R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 9, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 9, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 20, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 2, 2016PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jun 27, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 25, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 25, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 22, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 21, 2016GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 21, 2016GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 21, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 20, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 20, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 20, 2016ALIEASSIGNED TO LIE—
Jun 13, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 10, 2016GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 10, 2016GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 10, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 10, 2016DOCKASSIGNED TO EXAMINER—
Mar 1, 2016MPMKNOTICE OF PSEUDO MARK E-MAILED—
Feb 29, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 29, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance